美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Zenas BioPharma Inc.

26.03

-0.0400-0.15%

成交量：284.79萬

成交額：7,427.13萬

市值：13.97億

市盈率：-5.75

高：27.79

開：26.19

低：25.87

收：26.07

52周最高：44.60

52周最低：6.11

股本：5,367.92萬

流通股本：2,107.19萬

量比：5.23

換手率：13.52%

股息：- -

股息率：- -

每股收益(TTM):-4.5278

每股收益(LYR):-11.8940

淨資產收益率：-68.33%

總資產收益率：-33.72%

市淨率：7.11

市盈率(LYR):-2.19

資料載入中...

總覽公司新聞資訊公告

Zenas BioPharma公布Obexelimab治療複發性多發性硬化症的2期Moonstone試驗結果，將於2026年Actrims論壇進行突破性平台展示

Zenas Biopharma, Inc.盤中異動股價大漲5.14%

Zenas Biopharma, Inc.盤中異動股價大漲5.12%報19.08美元

Zenas Biopharma, Inc.盤中異動早盤急速下挫5.12%

美國研究綜述-不倫瑞克、派克-漢尼汾、XPLR 基礎設施

Zenas BioPharma股價因免疫疾病藥物後期數據不佳而跌至逾四個月低點，日內跌幅達55%

Zenas 生物製藥公司的免疫紊亂藥物在後期試驗中達到主要目標

Zenas BioPharma公布Obexelimab治療IgG4相關疾病3期INDIGO註冊試驗積極結果

InnoCare Pharma宣佈Orelabrutinib（Btk抑制劑）在系統性紅斑狼瘡的2B期研究中實現主要終點

Zenas BioPharma：Obexelimab三期Indigo試驗在免疫球蛋白G4相關疾病（IgG4-RD）中的初步結果預計將在年末公布

Zenas Biopharma公布Obexelimab在複發性多發性硬化症II期Moonstone試驗中取得積極結果

Zenas Biopharma預計將在2026年第一季度啓動Orelabrutinib針對繼發漸進性多發性硬化症患者的全球三級臨床試驗

Zenas Biopharma向SEC申請最多出售630萬股普通股的架構籌資

Zenas BioPharma：市場發行招股説明書涵蓋根據銷售協議可能發行的最多2億美元普通股

嗡嗡聲--美國股票走勢-聯合租賃、戴爾、Datadog

嗡嗡聲--美國股票走勢-英特爾、斯倫貝謝、聯邦快遞

Zenas BioPharma Inc.新型口服IL-17AA/AF抑制劑和口服透腦TYK2抑制劑預計2026年啓動一期臨床試驗

Zenas BioPharma Inc.與諾誠健華宣佈簽署許可協議，授予Zenas三項自身免疫候選產品的權益，其中包括BTK抑制劑奧雷巴替尼，該藥物正處於多發性硬化症三期臨床開發階段

諾誠健華表示總支付款項連同研發、監管里程碑及商業化里程碑付款超過20億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ZBIO/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":26.03,"timestamp":1772053200000,"preClose":26.07,"halted":0,"volume":2847890,"delay":0,"changeRate":-0.001534330648254666,"floatShares":21071865,"shares":53679166,"eps":-4.527832,"marketStatus":"盤前交易","change":-0.04,"latestTime":"02-26 05:48:47 EST","open":26.19,"high":27.79,"low":25.87,"amount":74271288.09701,"amplitude":0.073648,"askPrice":28,"askSize":1895,"bidPrice":23.78,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.527832,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1772116200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":26.03,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.03,"preClose":26.03,"latestTime":"19:59 EST","volume":4703,"amount":122400.14,"timestamp":1772067551432,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":5.2331566531585425,"impliedVol":0.9901,"impliedVolPercentile":0.5467},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":21071865,"roa":"-33.72%","roe":"-68.33%","lyrEps":-11.893967,"volumeRatio":5.2331566531585425,"shares":53679166,"dividePrice":0,"high":27.79,"amplitude":0.073648,"preClose":26.07,"low":25.87,"week52Low":6.11,"pbRate":"7.11","psRate":"93.15","week52High":44.6,"institutionHeld":0,"latestPrice":26.03,"committee":-0.899749,"eps":-4.527832,"divideRate":0,"volume":2847890,"delay":0,"ttmEps":-4.527832,"open":26.19,"prevYearClose":36.31,"prevWeekClose":25.88,"prevMonthClose":18.37,"prevQuarterClose":36.31,"fiveDayClose":26.68,"twentyDayClose":20.07,"sixtyDayClose":40.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"盤前","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25},{"market":"US","date":"2025-05-15","symbol":"ZBIO","fiscalQuarterEnding":"2025/03","expectedEps":-1.15,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1768107600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-02-25","current":-5.748888,"percent":0.259669,"low":-19.592941,"twenty":-9.905399,"median":-4.034228,"eighty":-2.509394,"high":-1.802568,"avg":-5.791777,"sd":4.137389,"marketCap":1399415857},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-13","current":-7.380571,"twenty":-10.08009,"median":-4.008147,"eighty":-2.503456,"marketCap":1401563024},{"date":"2026-02-20","current":-7.637803,"twenty":-9.946669,"median":-4.026371,"eighty":-2.50452,"marketCap":1450411065},{"date":"2026-02-25","current":-7.369264,"twenty":-9.905399,"median":-4.034228,"eighty":-2.509394,"marketCap":1399415857}],"updateTime":1772102927992},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1101729423","title":"Zenas BioPharma公布Obexelimab治療複發性多發性硬化症的2期Moonstone試驗結果，將於2026年Actrims論壇進行突破性平台展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1101729423","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101729423?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 20:07","pubTimestamp":1770638833,"startTime":"0","endTime":"0","summary":"Zenas BioPharma（纳斯达克代码：ZBIO）近日宣布，其针对复发性多发性硬化症研发的药物Obexelimab，在2期Moonstone临床试验中取得重要成果。这些突破性数据将于2026年在美国Actrims论坛上，以“最新突破性平台展示”的形式进行公布。\n此次公布标志着Obexelimab在治疗自身免疫性疾病领域迈出关键一步，也为全球多发性硬化症患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2609651785","title":"Zenas Biopharma, Inc.盤中異動 股價大漲5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609651785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609651785?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 22:41","pubTimestamp":1770388865,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日22时41分，Zenas Biopharma, Inc.股票出现异动，股价急速上涨5.14%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Klotho Neurosciences Inc C/Wts 21/06/2029 、Liminatus Pharma Inc C/Wts 30/04/2030 涨幅较大，Clearmind Medicine Inc.、Liminatus Pharma, Inc.、Aim Immunotech Inc.较为活跃，换手率分别为418.51%、18.28%、15.33%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Cingulate Inc C/Wts 10/12/2026 、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为47.83%、21.54%、18.03%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206224106a6dc117c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206224106a6dc117c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2608539373","title":"Zenas Biopharma, Inc.盤中異動 股價大漲5.12%報19.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608539373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608539373?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 23:05","pubTimestamp":1770131141,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日23时05分，Zenas Biopharma, Inc.股票出现异动，股价大幅上涨5.12%。截至发稿，该股报19.08美元/股，成交量8.8393万股，换手率0.16%，振幅5.45%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.86%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020323054197a4b3ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020323054197a4b3ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2605455713","title":"Zenas Biopharma, Inc.盤中異動 早盤急速下挫5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605455713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605455713?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 00:21","pubTimestamp":1769012470,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日00时21分，Zenas Biopharma, Inc.股票出现波动，股价快速跳水5.12%。Zenas Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。其相关个股中，Lisata Therapeutics, Inc.、Moolec Science Sa、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Aditxt, Inc.、Revelation Biosciences, Inc.、Lisata Therapeutics, Inc.较为活跃，换手率分别为1204.36%、81.52%、46.59%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Jasper Therapeutics Inc C/Wts 24/09/2026 、Io Biotech, Inc.，振幅分别为71.60%、68.10%、45.77%。Zenas Biopharma, Inc.公司简介：泽纳仕生物有限公司是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122002110a4465546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122002110a4465546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601043864","title":"美國研究綜述-不倫瑞克、派克-漢尼汾、XPLR 基礎設施","url":"https://stock-news.laohu8.com/highlight/detail?id=2601043864","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601043864?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 15:54","pubTimestamp":1767686040,"startTime":"0","endTime":"0","summary":"美国研究综述-不伦瑞克、派克-汉尼汾、XPLR 基础设施路透1月6日 - 华尔街证券分析师周二修订了对几家美国上市公司的评级和目标价，其中包括 Brunswick、Parker-Hannifin 和 XPLR Infrastructure。股票条目按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4S3Y70G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0353189763.USD","DC","WLTH","PH","SG9999014013.SGD","RJF","ROL","LU0175139822.USD","LU1732800096.USD","AGIO","BK4137","SNDR","ZBIO","LPLA","LU0300736062.USD","CWST","EXPD","BK4146","SCHW","BK4141","ALB","LU0348723411.USD","VRSN","IE00B7SZL793.SGD","CTAS","LU0211331839.USD","LU1046421795.USD","LU2237443465.HKD","BC","BK4561","XIFR","BK4547","LU0566484027.USD","LU0278409577.USD","LU0528227936.USD","LU1983260115.SGD","BK4605","MAN","TRV","LU1548497426.USD","HUBG","IBKR","LU2360107671.USD","MCHP","BBBY","LU1121112475.USD"],"gpt_icon":1},{"id":"1195864515","title":"Zenas BioPharma股價因免疫疾病藥物後期數據不佳而跌至逾四個月低點，日內跌幅達55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195864515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195864515?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 23:30","pubTimestamp":1767627041,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) 股价近日遭遇重挫，创下逾四个月以来的新低。此次股价大幅下跌的主要原因是其免疫疾病药物的后期临床试验数据未达市场预期，导致投资者信心受挫。截至最新交易时段，该公司股价当日跌幅高达55%，反映出市场对其药物研发前景的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2601810808","title":"Zenas 生物製藥公司的免疫紊亂藥物在後期試驗中達到主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2601810808","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601810808?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 21:25","pubTimestamp":1767619521,"startTime":"0","endTime":"0","summary":"路透1月5日 - Zenas生物制药公司ZBIO.O周一称，在一项针对罕见的免疫系统相关疾病患者的后期研究中，该公司的实验性药物降低了疾病复发的风险。该公司说，Zenas 公司的药物在其他四个次要目标上的表现也优于安慰剂，包括实现完全缓解的患者比例。Zenas 计划今年 寻求 美国和欧洲监管机构的批准 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4T3Y60VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837300.USD","LU0225771236.USD","LU1868837136.USD","BK4566","LU1291159041.SGD","BK4532","LU2242646821.SGD","LU1718418525.SGD","LU1571399168.USD","BMY","LU0061475181.USD","LU1868836914.USD","BK4588","BK4559","LU0096364046.USD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU1670711123.USD","BK4581","LU1868836591.USD","LU0868494617.USD","LU0985481810.HKD","IE00B2B36J28.USD","LU1989771016.USD","LU0306807586.USD","LU1670710588.SGD","LU1868836757.USD","IE00BJJMRZ35.SGD","ZBIO","LU0321505868.SGD","AMGN","BK4585","BK4534","LU1585245621.USD","IE00BSNM7G36.USD","BK4139","IE0002141913.USD","LU0289739699.SGD","LU0889565916.HKD","LU0237698245.USD","LU0122379950.USD","LU0267386448.USD","LU2089984988.USD","LU0320765992.SGD","SG9999001440.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU2242652126.USD","LU1093756325.SGD"],"gpt_icon":0},{"id":"1165846039","title":"Zenas BioPharma公布Obexelimab治療IgG4相關疾病3期INDIGO註冊試驗積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1165846039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165846039?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 20:06","pubTimestamp":1767614762,"startTime":"0","endTime":"0","summary":"Zenas BioPharma宣布，其药物Obexelimab在针对免疫球蛋白G4相关疾病（IgG4-RD）的3期INDIGO注册试验中取得了积极成果。该试验达到了主要终点，显示出显著疗效和良好安全性，为后续监管申报奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1133394639","title":"InnoCare Pharma宣佈Orelabrutinib（Btk抑制劑）在系統性紅斑狼瘡的2B期研究中實現主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=1133394639","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133394639?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 20:07","pubTimestamp":1765800457,"startTime":"0","endTime":"0","summary":"InnoCare Pharma宣布在针对系统性红斑狼疮的Orelabrutinib（Btk抑制剂）2B期研究中实现了主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1142056905","title":"Zenas BioPharma：Obexelimab三期Indigo試驗在免疫球蛋白G4相關疾病（IgG4-RD）中的初步結果預計將在年末公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1142056905","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142056905?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 20:13","pubTimestamp":1762949593,"startTime":"0","endTime":"0","summary":"Zenas BioPharma：Obexelimab三期Indigo试验在免疫球蛋白G4相关疾病（IgG4-RD）中的初步结果预计将在年末公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1122038621","title":"Zenas Biopharma公布Obexelimab在複發性多發性硬化症II期Moonstone試驗中取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1122038621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122038621?lang=zh_tw&edition=fundamental","pubTime":"2025-10-27 19:08","pubTimestamp":1761563296,"startTime":"0","endTime":"0","summary":"Zenas Biopharma公布Obexelimab在复发性多发性硬化症II期Moonstone试验中取得积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1165438252","title":"Zenas Biopharma預計將在2026年第一季度啓動Orelabrutinib針對繼發漸進性多發性硬化症患者的全球三級臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165438252","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165438252?lang=zh_tw&edition=fundamental","pubTime":"2025-10-27 19:08","pubTimestamp":1761563293,"startTime":"0","endTime":"0","summary":"Zenas Biopharma预计将在2026年第一季度启动Orelabrutinib针对继发渐进性多发性硬化症患者的全球三级临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1122167777","title":"Zenas Biopharma向SEC申請最多出售630萬股普通股的架構籌資","url":"https://stock-news.laohu8.com/highlight/detail?id=1122167777","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122167777?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 04:49","pubTimestamp":1761079748,"startTime":"0","endTime":"0","summary":"Zenas Biopharma向SEC申请最多出售630万股普通股，出售股东为卖方。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1182685701","title":"Zenas BioPharma：市場發行招股説明書 涵蓋根據銷售協議可能發行的最多2億美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1182685701","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182685701?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 04:37","pubTimestamp":1759955838,"startTime":"0","endTime":"0","summary":"Zenas BioPharma：市场发行招股说明书 涵盖根据销售协议可能发行的最多2亿美元普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2573927059","title":"嗡嗡聲--美國股票走勢-聯合租賃、戴爾、Datadog","url":"https://stock-news.laohu8.com/highlight/detail?id=2573927059","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573927059?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 23:43","pubTimestamp":1759938189,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数.DJI上涨0.30%，报46,740.90点。标准普尔500指数.SPX上涨0.52%，报6749.45点；纳斯达克综合指数.IXIC上涨0.77%，报22964.05点。nL3N3VP0QB ** Elf Beauty Inc < ELF.N  >:BUZZ - 因摩根士丹利以 Rhode 护肤品业绩为由上调 PT 值而上涨   nL6N3VP0MZ ** Equifa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nL3T3VP0ZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0300736492.USD","PSX","SLB","LU0433182093.SGD","HOTH","LU0310800965.SGD","DDOG","LU0053671581.USD","BK4123","HL","CAT","WERN","ARCB","CRVO","IE0002270589.USD","LU0498741890.SGD","SCCO","EFX","DELL","ELF","SMTC","LU2498475776.HKD","FRPT","ZBIO","CDE","CTVA","HOWL","LYV","CMI","BLD","LU1242518857.USD","URI","LU0122376428.USD","CFLT","F","LU2211817866.USD","LU0788108826.HKD","FDX","NEXT","NEM","JEF","LU0154245673.USD","CVS"],"gpt_icon":1},{"id":"2573928824","title":"嗡嗡聲--美國股票走勢-英特爾、斯倫貝謝、聯邦快遞","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928824","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928824?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 19:46","pubTimestamp":1759924015,"startTime":"0","endTime":"0","summary":".N** 英特尔公司 < INTC.O  >：BUZZ - 下跌；汇丰银行下调该股评级，原因是代工厂表现疲软，交易不明确。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nL3S3VP0O5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345780950.USD","BK4139","LU0300736062.USD","NEM","HL","ZBIO","LU2148611432.USD","LU1430597077.USD","LU2237438978.USD","LU0278409577.USD","LU0612318385.USD","BK4612","BK4551","LU0724618789.USD","LU1720051017.SGD","BK4131","BK4613","BK4023","LU1489326972.SGD","SLB","IE00B19Z3B42.SGD","LU0048573561.USD","BK4543","CDE","FDX","LU0300736492.USD","LU1023059493.AUD","LU0321505439.SGD","BK4515","ESPR","BK4585","LU0345780281.USD","LU2236285917.USD","LU0654597011.USD","BK4602","INTC","LU0068578508.USD","LU0788108826.HKD","BK4534","IE00B0JY6N72.USD","LU1883866441.USD","LU1280957306.USD","LU0788109121.HKD","BK4550","AU","LU0081259029.USD","CFLT","BK4529"],"gpt_icon":1},{"id":"1146091822","title":"Zenas BioPharma Inc.新型口服IL-17AA/AF抑制劑和口服透腦TYK2抑制劑預計2026年啓動一期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1146091822","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146091822?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 17:06","pubTimestamp":1759914392,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.的新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计将于2026年开始一期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","ZBIO","BK0239","BK4139"],"gpt_icon":0},{"id":"1121287790","title":"Zenas BioPharma Inc.與諾誠健華宣佈簽署許可協議，授予Zenas三項自身免疫候選產品的權益，其中包括BTK抑制劑奧雷巴替尼，該藥物正處於多發性硬化症三期臨床開發階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1121287790","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121287790?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 17:00","pubTimestamp":1759914020,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","ZBIO","BK0239","BK4139"],"gpt_icon":0},{"id":"1170408200","title":"諾誠健華表示總支付款項連同研發、監管里程碑及商業化里程碑付款超過20億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170408200","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170408200?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 16:58","pubTimestamp":1759913894,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，包括研发里程碑付款、监管里程碑付款和商业化里程碑付款在内的总支付款项已超过20亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","ZBIO","BK0239","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}